SCHEMBL4516152

SCHEMBL4516152

CN[C@H]1COc2c(S(=O)(=O)Nc3ccccc3)ccc(OC)c2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.43
HSD17B2 P37059 1/20 0.43
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
FABP4 P15090 4/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
LMNA P02545 1/20 0.41
ALOX12 P18054 1/20 0.41
ALDH1A1 P00352 2/20 0.40
GLA P06280 2/20 0.40
CYP3A4 P08684 2/20 0.40
MAPT P10636 2/20 0.40
CYP2C9 P11712 2/20 0.40
TSHR P16473 1/20 0.40
BRD4 O60885 1/20 0.40
BRD2 P25440 1/20 0.40
BRD3 Q15059 1/20 0.40
CYP19A1 P11511 1/20 0.39
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4513583 0.89 TP53 (0.43) MEN1KMT2ALMNAALDH1A1GLA
SCHEMBL4513550 0.89 FABP4 (0.44) HSD11B1HSD17B2CA12CA9FABP4
SCHEMBL4512924 0.87 MEN1 (0.47) MEN1KMT2ALMNAALDH1A1GLA
SCHEMBL4513542 0.87 PI4KB (0.42) HSD11B1HSD17B2MEN1KMT2AALDH1A1
SCHEMBL4523370 0.86 CA12 (0.43) HSD11B1HSD17B2CA12CA9FABP4
SCHEMBL4527056 0.85 TP53 (0.48) HSD11B1HSD17B2MEN1KMT2AALDH1A1
SCHEMBL4512114 0.85 MAPT (0.49) HSD11B1HSD17B2MEN1KMT2ALMNA
SCHEMBL4509228 0.85 HTR6 (0.44) HSD11B1HSD17B2MEN1KMT2ALMNA
SCHEMBL13889130 0.84 FABP4 (0.41) HSD11B1HSD17B2CA12CA9FABP4
SCHEMBL4512345 0.84 FABP4 (0.41) HSD11B1HSD17B2CA12CA9FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US claimed
EP-1888518-A1 NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP claimed
WO-2006126938-A1 NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO claimed
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US disclosed
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US disclosed
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor ASTRAZENECA AB (SE) 2009-04-16 US disclosed
EP-1888518-A1 NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP disclosed
WO-2006126938-A1 NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099187-A1 Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor HTR6, HTR1D, HTR1A HSD11B1 2184/4885HSD17B2 2494/4885CA12 4460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.